You've developed a novel technology and want to bring it to market in the US. Now what? Can you submit as a breakthrough device, or is the de novo route a better choice? How are they different? How are they similar? 

Breathe - and listen in as Michelle walks you through the options.

Breakthrough, de novo, or PMA? FDA Submission Pathways for Novel Devices

Upload to EUDAMED is a requirement of MDR, but adoption has been slower than anticipated. Manufacturers are reluctant to invest in the time required to upload their product catalog, and the platform itself has been plagued with issues. Listen in as Richard Houlihan lifts the curtain on why industry has been reluctant to embrace EUDAMED and what the future might hold for both sides.

EUDAMED Update: January 2023

MDR has been puzzling me for a few years now, and it's getting worse, not better. In this webinar hosted by Greenlight Guru, we look at the data gathered from recent MDCG guidance documents, industry and notified body surveys, and personal interviews with stakeholders (including notified bodies) who shared their first-hand experiences with implementation (spoiler alert: it ain't pretty).

MDR By The Numbers: Leveraging New Data for Implementation Planning

The best leaders know that quality is much more than a box to be checked, or a necessary evil to be endured along the road to FDA (or MDR) approval.

This is the third in a series of conversations talking about quality and how it can actually benefit a company, and even give you an advantage over your competition.

Make Quality Make $en$e:  Management's Role in Quality

You may think document control is boring, but wait until you hear these stories:

Red-lined post-it notes. Uncontrolled copies passed around during inspections. Master files stored on a desktop instead of in the eQMS system. Secret file cabinets in locked closets full of uncontrolled, red-lined specifications documents.

Oh, the joy of document control!

The Joy of Document Control

Many manufacturers see quality as a necessary evil, a box to be checked just to placate the FDA on the way to market launch. But it can be SO much more.

In this episode, Ti Benson and I discuss how quality can actually be a business benefit and not simply something to be endured.

The Business Benefits of Quality

As medical devices become more connected, concerns about security increase, leaving manufacturers - and regulatory staff - uncertain as to the best path forward. Listen in as Michelle and guest Randy Horton discuss industry needs and what the FDA plans to do to ensure the safety of connected and AI-driven devices.

Medical Devices, Cloud Computing and Cybersecurity with Randy Horton

When is it better for a medtech startup to hire a fractional quality professional, and when is it time to hire full-time? 

This is not necessarily an easy question to answer, and there can be a lot of factors impacting the decision. 

In this joint podcast with Mitch Robbins, we discuss the challenges and opportunities of today's topsy-turvy QA hiring market, and why many companies are opting for fractional QA professionals rather than full-time employees.

Fractional or Full Time Quality Support: Which is Right for You?

Question, questions, everyone has questions about eSTAR 5.0, so I sat down with the FDA's Patrick Axtell to answer the most pressing ones I've received.

From file size to eSTAR type to biocompatibility - we cover it all.

eSTAR 5.0 Q+A with Patrick Axtell from the FDA

Why would you use a 3rd party reviewer for your submission? How does a 3rd party reviewer function? How is it different from working with the FDA?

I sat down with my good friend Shawnnah Monterrey from Beanstock Ventures to answer all your pressing questions about using 3rd party reviewers.

The Benefits of 3rd Party FDA Reviewers

This is not last year's eSTAR - a LOT has changed, and there are things you need to know before you try to submit your 510k. 

In this episode, we'll guide you through the intricacies of the latest eSTAR 5.0 platform, crucial for those of you planning a 510k or PMA submission.

We'll review the eSTAR 5.0 platform and what you need to know to use it effectively –the good, the bad, and the ugly.

The new features, including premarket approval content and updated cybersecurity documentation and dive into the simplified EMC questions, revised sterility section, and new biocompatibility testing options - we'll cover it all.

Breakthrough, de novo, or PMA? FDA Submission Pathways for Novel Devices

RAQA Today

Related tracks